Bashkim Ziberi, PhD

Chief Scientific Officer and Co-Founder at Quantum Theranostics

Bashkim Ziberi is a nanoparticle engineering, quantum system design, and translational medical technology. With a strong background in both applied physics and biomedical engineering, he leads QTX's technical architecture, nanoscale modeling, and risk management frameworks.

Mr. Ziberi's expertise includes materials engineering, nanoparticle-radiation interactions, development of novel nanoscale delivery agents, and integration of nanotechnology with entanglement-driven detection. At QTX, he is responsible for the design, development, and feasibility assessment of all system hardware, ensuring seamless translation of QTX inventions into clinical-grade devices.

His leadership focuses on bridging deep-tech physics and engineering with clinical implementation, positioning , QTX as the first platform to harness nanoparticles not only for therapy enhancement but also as quantum photon sources inside living systems..

Ruth Beassem, M.A.

Chief of Staff and Co-Founder at Quantum Theranostics

Ruth Beassem is an experienced executive specializing in strategic coordination, internal operations, and organizational leadership for complex, multidisciplinary teams. She holds a Masters in Cross Cultural and Sustainable Business Management. At QTX, she serves as Chief of Staff, where she manages executive synchronization, team cadence, and strategic project tracking.

She is responsible for ensuring cross-disciplinary communication, aligning technical, clinical, and business objectives, and coordinating the company's board and advisory logistics. With a background in healthcare operations and organizational management, Ms. Beassem plays a critical role in enabling QTX's global operations to function cohesively and efficiently.

Her leadership extends to supporting the strategic execution of QTX's roadmap, helping to align the company's scientific vision with practical deliverables and ensuring that all stakeholders from clinical partners to investors remain fully engaged and informed.

Horacio Bustos, MBA

Chief Commercial Officer at Quantum Theranostics

Horacio Bustos is a seasoned business executive with over 20 years of experience leading sales and marketing organizations at Fortune 500 companies including Intel Corporation and other high-tech communications leaders. Holding an MBA degree, he specializes in business development, new market entry, and driving revenue growth in the dynamic semiconductor and telecommunications sectors..

In his tenure at Intel and prominent high-tech communications firms, Horacio has directed global sales strategies, spearheaded multimillion-dollar partnerships, and accelerated adoption of cutting-edge technologies across emerging markets., His leadership in optimizing channel programs, launching innovative product campaigns, and expanding into high-growth regions has consistently delivered double-digit revenue gains and strengthened competitive positioningfor industry giants...

A strategic visionary with deep expertise in data-driven marketing, ecosystem development, and cross-functional collaboration Horacio excels at navigating complex regulatory landscapes and volatile tech cycles. Renowned for building high-performance teams and mentoring next-generation leaders, he remains a trusted advisor in the global high-tech executive community.

Dr. Gustavo H. Olivera, Ph.D., MBA, FACHE, CPHQ, CGBLSS

Chairman of the Board and CEO

See Executive Leadership Team section above for full biographical summary

Fattin Abu Nimeh, MBA

Independent Director and Strategic Advisor

Fattin Abu Nimeh, MBA, is a seasoned healthcare executive and strategic advisor with more than 30 years of experience spanning clinical care, global health systems, and healthcare technology. Her career began in direct patient care and evolved into senior commercial and leadership roles across international healthcare markets, where she has led growth strategy, partnerships, and large-scale transformation initiatives across EMEA, Central Asia, and India. With deep expertise in healthcare operations, commercialization, and digital health, Fattin has worked extensively with complex health systems to advance enterprise solutions that improve both clinical and financial performance.

Today, Fattin serves as a trusted strategic advisor to global healthcare organizations, investors, and innovators, guiding them through digital transformation, patient experience strategy, and value-driven care models, while also supporting early-stage healthcare and health technology companies in preparing for and securing funding from high-quality, strategic investors. As a CEO and thought leader, she is recognized for her ability to bridge clinical insight with technology, data, and human-centered design to deliver measurable, sustainable outcomes. Her work focuses on helping health systems and health technology companies align strategy, execution, and culture to scale impact, enhance patient engagement, and navigate complex global healthcare environments, particularly across EMEA and emerging markets.

Betta Sherman Swanson, MPP

Independent Director

Betta Sherman Swanson is a nationally recognized healthcare compliance and integrity leader with over 15 years of experience building and managing enterprise-wide compliance programs for complex healthcare organizations. She currently serves as Chief Integrity Risk and Compliance Officer at Elara Caring, Inc. (since June 2023), where she oversees an integrated team of compliance, privacy, legal, risk, safety and quality professionals for a greater than $1B home-based care company with 27,000 employees operating across 18 states. She serves as expert advisor to the executive team and Board of Directors on all compliance, HIPAA, regulatory, risk and safety matters.

During her tenure at Elara Caring, Ms. Sherman Swanson developed a best-in-class workplace violence prevention program that led to a 10-point increase in team member safety perception scores, 31 points above the national healthcare benchmark. She successfully resolved a Department of Justice False Claims Act investigation into pre-merger hospice eligibility concerns, averting a Corporate Integrity Agreement and minimizing fines through her robust, proactive compliance program. Her speak-up campaign emphasizing duty to report and just culture resulted in a 20% increase in voluntary compliance reports with an anonymous reporting rate of less than 1%, underscoring a strong culture of trust.

Prior to Elara Caring, Ms. Sherman Swanson served as Chief Compliance Officer at 21st Century Oncology (2016 to 2020), where she built and managed the enterprise-wide compliance program for a national 300-site, 500-physician integrated cancer care network. She successfully managed all implementation and ongoing requirements under a medical necessity and Stark/Anti-Kickback Corporate Integrity Agreement with the Office of Inspector General (OIG) and an information.

Mohammed Saiful Huq, PhD

Director and Co-Founder

Prof. Mohammed Saiful Huq, PhD, FAAPM, FInstP, is a global leader in medical physics and oncology innovation with over three decades of experience advancing clinical physics, radiotherapy quality, and international cancer care. He is Professor of Radiation Oncology at the University of Pittsburgh School of Medicine and Director of the Medical Physics Division at UPMC Hillman Cancer Center, where he oversees radiation oncology physics operations across 26 UPMC Hillman sites in the United States and provides guidance for medical physics services at four UPMC sites in Ireland and Italy.

Prof. Huq has authored 189 peer-reviewed publications and delivered more than 240 invited talks globally. He served as President of the American Association of Physicists in Medicine (AAPM) in 2020 and as Chairman of the AAPM Board of Directors in 2021. In 2023, he received the William D. Coolidge Gold Medal, the highest honor bestowed by the AAPM, for his distinguished career and significant impact on the science and practice of medical physics. In 2024, he was awarded the U.S. Presidential Gold Medal and Lifetime Achievement Award, one of the highest civilian honors in the United States, in recognition of his exceptional contributions to cancer care, medical physics, education, research, and health equity.

Prof. Huq is a Fellow of both the American Association of Physicists in Medicine and the Institute of Physics (UK). He received the Inaugural Gold Medal from the Asia and Middle East Society of Therapeutic Radiation and Oncology (AMSTRO), where he serves as Vice President, recognizing his pivotal role in establishing AMSTRO and organizing its first conference with participants from 64 countries. He is a strong advocate for improving the quality of cancer care globally, particularly in low- and middle-income countries, and has contributed significantly to the education and training of medical physicists across Africa, South Asia, Eastern Europe, and the Middle East.

Role in Quantum Theranostics (QTX):

As Director and Co-Founder, Prof. Huq provides strategic guidance on clinical physics, radiotherapy quality standards, and global health strategy. He serves as Principal Investigator on the ARPA-H grant application currently in final review, leading a multi-institutional collaboration with the University of Pittsburgh, University of Pennsylvania, and University of Massachusetts Lowell.

Bashkim Ziberi, PhD

Director and Co-Founder

See Executive Leadership Team section above for full biographical summary

Dr. Steven Avery, PhD

Director and Co-Founder

Dr. Steven Avery, PhD, FAAPM, is a Professor of Radiation Oncology and Director of Global Radiation Physics at the University of Pennsylvania. He brings over two decades of leadership in radiation oncology physics, translational research, and international technology deployment, with a strong track record of fostering multidisciplinary partnerships to advance innovative cancer care solutions.

Dr. Avery is a medical physicist specializing in proton therapy, with clinical work focused on commissioning new treatment modalities, developing advanced planning techniques, machine and patient quality assurance, and innovating detection methods to improve treatment safety and effectiveness. He holds a PhD in Experimental Nuclear Physics from Hampton University and a BS in Physics from Millersville University.

Dr. Avery is co-Director of the Global Health Catalyst Summit at the University of Pennsylvania, bringing together WHO officials, policymakers, ministries of health, industry, and academic partners to establish cancer centers, expand telehealth, conduct multi-country clinical trials, and strengthen healthcare systems. His work has contributed to the Lancet Oncology Commission for sub-Saharan Africa and new U.S.-Africa collaborations announced during the 2022 U.S.-Africa Leaders’ Summit. He has received the United States President’s Lifetime Achievement Award in recognition of his contributions to science, service, and community advancement.

Role in Quantum Theranostics (QTX):

As Director and Co-Founder, Dr. Avery defines the strategic direction for the development and international rollout of QTX’s quantum medicine platform. He ensures that scientific innovation is aligned with clinical priorities and operational realities, guiding the adaptation of QTX technologies for real-world healthcare environments. His work centers on building institutional and technical partnerships essential for effective implementation across a range of clinical settings.

Dr. Thomas “Rock” Mackie, PhD

Scientific Advisor

Dr. Thomas “Rock” Mackie, PhD, is Professor Emeritus of Medical Physics at the University of Wisconsin-Madison, co-founder and former Chairman of TomoTherapy Inc., and one of the most influential figures in modern radiation oncology technology. He is the primary inventor and algorithm designer of the helical TomoTherapy concept, a technology that transformed radiation treatment delivery worldwide.

TomoTherapy went public in 2007 with an IPO market capitalization exceeding $960 million and was later acquired by Accuray. Dr. Mackie also co-founded Geometrics Corporation, which developed the Pinnacle treatment-planning system, now part of Philips Medical Systems.

He has received the ASTRO Gold Medal Award (2019) and the AAPM Coolidge Gold Medal (2014), the two highest honors in the fields of radiation oncology and medical physics respectively. Dr. Mackie is a Fellow of the American Association of Physicists in Medicine (AAPM) with over 180 peer-reviewed publications and 40+ issued patents.

Role in Quantum Theranostics (QTX):

Dr. Mackie’s guidance at Quantum Theranostics focuses on technology translation, product-development governance, and long-term industrial strategy. His unparalleled experience in bringing revolutionary radiation oncology technologies from concept to global commercial success provides invaluable

Hedvig (Hedi) Hricak, M.D., Ph.D., Dr. (h.c.m)

Scientific Advisor

Dr. Hedvig (Hedi) Hricak, M.D., Ph.D., Dr. (h.c.m), is Emeritus Chair of Radiology at Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, and a leading figure in the field of radiology. She served as Chair of the Department of Radiology at MSKCC from 1999 to early 2023 and, until she transitioned to an emeritus position in August 2025, was a member of the Molecular Pharmacology Program at the Sloan Kettering Institute, and a Professor at the Gerstner Sloan Kettering Institute of Biomedical Sciences. She is an Emeritus Professor of Radiology at Weill Cornell College of Medicine, New York, NY.

Dr. Hricak is a prolific writer with over 800 peer-reviewed publications, 18 books, and several monographs. She was an NIH-funded investigator from the 1985s through the end of her tenure at MSK. The hallmark of her academic career has been the development, translation, and dissemination of diagnostic imaging techniques, including molecular imaging and theranostics, primarily for the treatment of genitourinary cancers. She is best known for helping develop and optimize MRI applications for gynecological and prostate cancers.

She is actively engaged in global health initiatives that promote international education and collaboration to enhance the quality and accessibility of oncologic imaging and cancer care. She recently co-chaired the steering committee that facilitated the passage of the 78th World Health Assembly (WHA) Resolution on Strengthening Medical Imaging Capacity. In addition, she was Chair of the Lancet Oncology Commission on Medical Imaging and Nuclear Medicine, served on the steering committee of the Lancet Oncology Commission on Radiotherapy and Theranostics, and is currently Co-chair of the Lancet Oncology Commission addressing the global cancer care workforce shortage.

In 2002, Dr. Hricak was elected a member of the National Academy of Medicine (NAM), part of the prestigious tripartite National Academies of Sciences, Engineering, and Medicine of the United States. She has served on the Nuclear and Radiation Studies Board of the National Academies. In 2018, she became the first radiologist ever to receive the David Rall Medal for distinguished leadership from the NAM. She is a member of the National Cancer Policy Forum.

Dr. Hricak is also a Foreign Member of the Croatian Academy of Science and Arts (2004) and a Foreign Member of the Russian Academy of Sciences (2011). She has received numerous awards including the Médaille Antoine Béclère (France, 2007), the Order of the Croatian Morning Star Presidential Award (2009), the Badge of Honor of the Medical University of Vienna (2017), and the Global Health Catalyst Award for advancing global health and economic development (2025). She has been awarded nine gold medals and 22 honorary fellowships from radiological societies worldwide. She holds honorary doctorates from Ludwig Maximilian University of Munich, Germany, and University of Toulouse III, Paul Sabatier, Toulouse, France.

Erno Sajo, PhD

Scientific Advisor

Dr. Erno Sajo is a Professor of Physics and the Director of Medical Physics at the University of Massachusetts Lowell, where he also serves as the Director of Biomedical Engineering and Biotechnology. He has an extensive record of peer-reviewed publications, patents, and collaborative research. He is internationally recognized for his expertise in radiation transport computations, spanning both deterministic methods and Monte Carlo simulation techniques, and for his fundamental contributions to the physics underpinning nanoparticle-aided radiotherapy.

A major focus of his work has been nanoparticle-enhanced radiotherapy, leveraging advanced computational models to understand and optimize dose enhancement effects in cancer treatment. His research integrates nanoscale physics with clinical radiation oncology to explore how high-atomic-number materials can be used to increase tumor dose deposition while sparing normal tissues.

In addition, Dr. Sajo is an inventor and developer of the nano-film High Energy Current (HEC) detector, a class of self-powered, thin-film radiation sensors for medical imaging, dosimetry, and radiation safety applications. These innovative detectors harness the energy of the radiation they measure and can be fabricated at low cost in scalable formats, offering new possibilities for real-time dose monitoring without external power or amplification. This technology has been the basis for translational collaborations and startup ventures focused on bringing next-generation radiation sensors to practice.

Apart from radiation physics, Dr. Sajo has also made significant contributions to nanoparticle transport (aerosols and hydrosols), including computational modeling of particle dynamics with applications in health and defense. His broad body of work reflects a commitment to bridging fundamental physical science with real-world applications in health, safety, and technology.

Role in Quantum Theranostics (QTX):

Characterization of quantum entanglement and entanglement preservation, nanoparticle radiation physics.